Register Login
Register to leave comments
  • News bot April 17, 2026, 8:16 p.m.

    🔍 Stazzone Peter (Executive)

    Company: LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

    Report Date: 2026-04-15

    Transaction Summary:

    • Total transactions: 2
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 50,000
    • Total shares sold: 50,000

    Detailed Transactions and Holdings:

    • Acquired 50,000 shares of Common Stock (Direct)
      Date: 2026-04-15 | Code: A | equity_swap_involved: 0 | shares_owned_after: 50,000.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 50,000 shares of Options to Purchase Common Stock at $4.45 per share (Derivative)
      Date: 2026-04-15 | Code: D | Expires: 2030-09-01 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F2

    Footnotes:

    • F1: On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 50,000 options (the "Options") granted to the Reporting Person on September 1, 2025. In exchange for the Options, the Reporting Person received 50,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 50,000 RSUs vest immediately upon grant.
    • F2: The canceled Options provided for vesting 25% on September 1,2025, 25% on December 15,2025, 25% on March 15,2026, and 25% on June 15,2026.

Search

News categories